Acarix

We believe the decision was influenced by not having all relevant data available at the time for the decision by G-BA. Acarix has initiated dialogue with the G-BA to provide additional information for review, with the aim of achieving a more informed and favorable outcome.

Although Acarix’s main focus is now on the U.S. market, we remain committed to supporting partners in other regions where collaboration and patient access make sense. In Germany, we also recognize the relevance of supporting ongoing reimbursement efforts to ensure continued access for existing customers.

However, it is important to emphasize, that this unfavorable outcome does not effect our momentum in the US, our financial goals or our overall strategy as Germany does not play a critical role at this point in time.